The concentration-dependent nature of in vitro amphotericin B-itraconazole interaction against Aspergillus fumigates:: isobolographic and response surface analysis of complex pharmacodynamic interactions

被引:29
作者
Meletiadis, Joseph
Dorsthorst, Debbie T. A. te
Verweij, Paul E.
机构
[1] NCI, Pediat Oncol Branch, NIH, Bethesda, MD 20892 USA
[2] Radboud Univ Nijmegen Med Ctr, Dept Med Microbiol, Nijmegen, Netherlands
关键词
antifungal interaction; isobolography; synergy and antagonism; bliss independence; Loewe additivity; response surface analysis;
D O I
10.1016/j.ijantimicag.2006.07.011
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The interaction between polyenes and azoles is not well understood. We therefore explored the in vitro combination of amphotericin B with itraconazole against 14 clinical Aspergillus fumigates isolates (9 itraconazole susceptible and 5 itraconazole resistant) with a colorimetric broth microdilution checkerboard technique using two drug interaction models able to explore complicated patterns of interactions: the response surface analysis of Bliss independence and the isobolographic analysis of Loewe additivity zero interaction theories. Synergy was found at combinations with low concentrations of amphotericin B (< 0.125 mg/L), whereas antagonism was found at combinations with higher concentrations of amphotericin B. For itraconazole-resistant isolates, synergistic interactions were observed at high concentrations of itraconazole (> 0.5 mg/L). Synergy was more frequently observed for the itraconazole-resistant isolates than for the itraconazole-susceptible isolates. (c) 2006 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:439 / 449
页数:11
相关论文
共 46 条
[1]   Comparative molecular dynamics simulations of amphotericin B-cholesterol/ergosterol membrane channels [J].
Baginski, M ;
Resat, H ;
Borowski, E .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 2002, 1567 (1-2) :63-78
[2]   MINOR SYNERGY AND ANTAGONISM MAY BE CLINICALLY IMPORTANT [J].
BERENBAUM, MC .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1987, 19 (02) :271-273
[3]  
BERENBAUM MC, 1989, PHARMACOL REV, V41, P93
[4]  
BERENBAUM MC, 1988, J ANTIMICROB CHEMOTH, V21, P497, DOI 10.1093/jac/21.4.497-a
[5]   Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive pulmonary aspergillosis [J].
Chandrasekar, PH ;
Cutright, JL ;
Manavathu, EK .
CLINICAL MICROBIOLOGY AND INFECTION, 2004, 10 (10) :925-928
[6]   Comparative efficacies of conventional amphotericin B, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis [J].
Clemons, KV ;
Espiritu, M ;
Parmar, R ;
Stevens, DA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (12) :4867-4875
[7]  
COHEN BE, 1986, BIOCHIM BIOPHYS ACTA, V857, P117
[8]   In vitro evaluation of double and triple combinations of antifungal drugs against Aspergillus fumigatus and Aspergillus terreus [J].
Dannaoui, E ;
Lortholary, O ;
Dromer, F .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (03) :970-978
[9]   An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: Diagnosis and therapeutic outcome [J].
Denning, DW ;
Marinus, A ;
Cohen, J ;
Spence, D ;
Herbrecht, R ;
Pagano, L ;
Kibbler, C ;
Kcrmery, V ;
Offner, F ;
Cordonnier, C ;
Jehn, U ;
Ellis, M ;
Collette, L ;
Sylvester, R .
JOURNAL OF INFECTION, 1998, 37 (02) :173-180
[10]  
*FDA ADV COMM, 2000, CASP AC